Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators

FASEB Journal

Volumn 21, Issue 14, 2007, Pages 3835-3844

  Zhu, Wen ^a,b   Xie, Wenjie ^a   Pan, Tianhong ^a   Xu, Pingyi ^b   Fridkin, Mati ^c   Zheng, Hailin ^c   Jankovic, Joseph ^a   Youdim, Moussa B H ^d   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

M30; Parkinson's disease; Ubiquitin proteasome system; VK 28

Indexed keywords

[5 (4 (2 HYDROXYETHYL) PIPERAZIN 1 YL (METHYL) 8 HYDROXYQUINOLINE]; [5 (N METHYL N PROPARGYAMINOMETHYL) 8 HYDROXYQUINOLINE]; IRON CHELATING AGENT; LACTACYSTIN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; IN VIVO STUDY; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ACETYLCYSTEINE; ANIMALS; BLOOD-BRAIN BARRIER; DOPAMINE; GOATS; HYDROXYQUINOLINES; IRON CHELATING AGENTS; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; RABBITS; SUBSTANTIA NIGRA;

MUS;

EID: 36849044036     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-8386com     Document Type: Article

References (53)

1. Siderowf, A., and Stern, M. (2003) Update on Parkinson disease. Ann. Intern. Med. 138, 651-658
2. Morrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., and Brooks, D. J. (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry 64, 314-319
3. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., and Youdim, M. B. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205
4. Berg, D., Becker, G., Riederer, P., and Rie, O. (2002) Iron in neurodegenerative disorders. Neurotox. Res. 4, 637-653
5. Gutteridge, J. M. (1992) Iron and oxygen radicals in brain. Ann. Neurol. 32 (Suppl.), S16-S21
6. Grunblatt, E., Mandel, S., Maor, G., and Youdim, M. B. (2001) Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77, 146-156
7. Mandel, S., Weinreb, O., Amit, T., and Youdim, M. B. (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem. 88, 1555-1569
8. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909
9. Gal, S., Zheng, H., Fridkin, M., and Youdim, M. B. (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95, 79-88
10. Jellinger, K. A. (2001) The pathology of Parkinson's disease. Adv. Neurol. 86, 55-72
11. Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., and Arendash, G. W. (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660, 8-18
12. Maruyama, W., Shamoto-Nagai, M., Akao, Y., Riederer, P., and Naoi, M. (2006) The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells. J. Neural Transm. Suppl. 70, 125-132
13. Mandel, S., Maor, G., and Youdim, M. B. (2004) Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. 24, 401-416
14. Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., and Le, W. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333, 544-549
15. Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., and Youdim, M. B. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46, 254-263
16. He, Y., Appel, S., and Le, W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187-193
17. Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B., and Fridkin, M. (2005) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative disease. Bioorg. Med. Chem. 13, 773-783
18. Goldberg, A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899
19. McNaught, K. S., and Olanow, C. W. (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27, 530-545
20. Grunblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., Li, J., Ravid, R., Roggendorf, W., Riederer, P., and Youdim, M. B. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543-1573
21. Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Busceti, C. L., Ruffoli, R., Soldani, P., Ruggieri, S., Alessandri, M. G., and Paparelli, A. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955-8966
22. McNaught, K. S., Perl, D. P., Brownell, A. L., and Olanow, C. W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56, 149-162
23. Manning-Bog, A. B., Reaney, S. H., Chou, V. P., Johnston, L. C., McCormack, A. L., Johnston, J., Langston, J. W., and Di Monte, D. A. (2006) Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60, 256-260
24. Bove, J., Zhou, C., Jackson-Lewis, V., Taylor, J., Chu, Y., Rideout, H. J., Wu, D. C., Kordower, J. H., Petrucelli, L., and Przedborski, S. (2006) Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60, 260-264
25. Kordower, J. H., Kanaan, N. M., Chu, Y., Suresh Babu, R., Stansell J 3rd, Terpstra, B. T., Sortwell, C. E., Steece-Collier, K., and Collier, T. J. (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60, 264-268
26. McNaught, K. S., and Olanow, C. W. (2006). Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60, 243-247
27. Gotz, M. E., Double, K., Gerlach, M., Youdim, M. B., and Riederer, P. (2004) The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012, 193-208 (review)
28. Hallgren, B., and Sourander, P. (1958) The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3, 41-51
29. Gerlach, M., Double, K. L., Youdim, and M. B., Riederer, P. (2006) Potential sources of increased iron in the substantia nigra of parkinsonian patients. J. Neural Transm. Suppl. 70, 133-142
30. Kaur, D., and Andersen, J. (2004) Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev. 3, 327-343
31. Theil, E. C., and Eisenstein, R. S. (2000) Combinatorial mRNA regulation: iron regulatory proteins and iso-iron-responsive elements (Iso-IREs). J. Biol. Chem. 275, 40659-40662
32. Cairo, G., and Pietrangelo, A. (2000) Iron regulatory proteins in pathobiology. Biochem. J. 352, 241-250
33. Wang, J., Fillebeen, C., Chen, G., Biederbick, A., Lill, R., and Pantopoulos, K. (2007) Iron-dependent degradation of Apo-IRP1 by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 27, 2423-2430
34. McNaught, K. S., Bjorklund, L. M., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2002) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuro-Report 13, 1437-1441
35. Gaeta, A., and Hider, R. C. (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146, 1041-1059
36. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer., M., and Wolozin B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054
37. Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., and Youdim, M. B. (2007) Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100, 490-502
38. Friedlich, A. L., Tanzi, R. E., and Rogers, J. T. (2007) The 5-′-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol. Psychiatry 12, 222-223
39. Turnbull, S., Tabner, B. J., El-Agnaf, O. M., Moore, S., Davies, Y., and Allsop, D. (2001) α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free. Radic. Biol. Med. 30, 1163-1170
40. Shamoto-Nagai, M., Maruyama, W., Yi, H., Akao, Y., Tribl, F., Gerlach, M., Osawa, T., Riederer, P., and Naoi, M. (2006) Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J. Neural Transm. 113, 633-644
41. Goswami, A., Dikshit, P., Mishra, A., Mulherkar, S., Nukina, N., and Jana, N. R. (2006) Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 342, 184-190
42. Block, M. L., Zecca, L., and Hong, J. S. (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69
43. Ke, Z. J., and Gibson, G. E. (2004) Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Int. 45, 361-369
44. Hirsch, E. C., Hunot, S., and Faucheux, B. (1999) Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord. 14, 383-385
45. Tatton, W. G., and Olanow, C. W. (1999) Apoptosis in neurodegenerative disease: the role of mitochondria. Biochim. Biophys. Acta 1410, 195-213
46. Le, W., Jankovic, J., Xie, W., Kong, R., and Appel, S. H. (1997) (-)-Deprenyl protection of 1-methyl-4 phenylpyridirm ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci. Lett. 224, 197-200
47. Nair, V. D., McNaught, K. S., Gonzalez-Maeso, J., Sealfon, S. C., and Olanow, C. W. (2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281, 39550-39560
48. Lotharius, J., Falsig, J., van Beek, J., Payne, S., Dringen, R., Brundin, P., and Leist, M. (2005) Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25, 6329-6342
49. Jimenez Del Rio, M., and Velez-Pardo, C. (2004) Transition metal-induced apoptosis in lymphocytes via hydroxyl radical generation, mitochondria dysfunction, and caspase-3 activation: an in vitro model for neurodegeneration. Arch. Med. Res. 35, 185-193
50. Lee, M., Hyun, D. H., Marshall, K. A., Ellerby, L. M., Bredesen, D. E., Jenner, P., and Halliwell, B. (2001) Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free. Radic. Biol. Med. 31, 1550-1559
51. Bar-Am, O., Weinreb, O., Amit, T,. and Youdim, M. B. (2005). Regulation of Bcl-2 family protein, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 13, 1899-1901
52. Youdim, M. B., Amit, T., Falach-Yogev, M., Am, O. B., Maruyama, W., and Naoi, M. (2003) The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol. 66, 1635-1641
53. Sagi, Y., Mandel, S., Amit, T., and Youdim, M. B. (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35-44